α-linolenic acid inhibits human renal cell carcinoma cell proliferation through PPAR-γ activation and COX-2 inhibition

Oncology Letters

Volumn 6, Issue 1, 2013, Pages 197-202

  Yang, Lijun ^a   Yuan, Jianlin ^a   Liu, Liwen ^a   Shi, Changhong ^b   Wang, Longxin ^a   Tian, Feng ^a   Liu, Fei ^a   Wang, He ^a   Shao, Chen ^a   Zhang, Qiang ^c   Chen, Zhinan ^b   Qin, Weijun ^a   Wen, Weihong ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

linolenic acid; Cell proliferation; Cyclooxygenase 2; Peroxisome proliferator activated receptor ; Renal cell carcinoma

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; LINOLENIC ACID; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYMATIC ASSAY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTRACELLULAR SIGNALING; KIDNEY CARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84878337941     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1336     Document Type: Article

References (46)

1. Motzer RJ, Bander NH and Nanus DM: Renal-cell carcinoma. N Engl J Med 335: 865-875, 1996.
2. Rini BI, Rathmell WK and Godley P: Renal cell carcinoma. Curr Opin Oncol 20: 300-306, 2008.
3. Rose DP and Connolly JM: Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther 83: 217-244, 1999.
4. Rashidkhani B, Akesson A, Lindblad P and Wolk A: Major dietary patterns and risk of renal cell carcinoma in a prospective cohort of Swedish women. J Nutr 135: 1757-1762, 2005.
5. Wolk A, Larsson SC, Johansson JE and Ekman P: Long-term fatty fish consumption and renal cell carcinoma incidence in women. JAMA 296: 1371-1376, 2006.
6. Spencer L, Mann C, Metcalfe M, Webb M, Pollard C, Spencer D, Berry D, Steward W and Dennison A: The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential. Eur J Cancer 45: 2077-2086, 2009.
7. Wendel M and Heller AR: Anticancer actions of omega-3 fatty acids -current state and future perspectives. Anticancer Agents Med Chem 9: 457-470, 2009.
8. Desvergne B and Wahli W: Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr Rev 20: 649-688, 1999.
9. Feige JN, Gelman L, Michalik L, Desvergne B and Wahli W: From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 45: 120-159, 2006.
10. Krishnan A, Nair SA and Pillai MR: Biology of PPAR gamma in cancer: a critical review on existing lacunae. Curr Mol Med 7: 532-540, 2007.
11. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM and Lehmann JM: Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci USA 94: 4318-4323, 1997.
12. Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Lehmann JM, Wisely GB, Willson TM, Kliewer SA and Milburn MV: Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell 3: 397-403, 1999.
13. Lim K, Han C, Dai Y, Shen M and Wu T: Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2. Mol Cancer Ther 8: 3046-3055, 2009.
14. Hashimoto Y, Kondo Y, Kimura G, Matsuzawa I, Sato S, Ishizaki M, Imura N, Akimoto M and Hara S: Cyclooxygenase-2 expression and relationship to tumour progression in human renal cell carcinoma. Histopathology 44: 353-359, 2004.
15. Khan KN, Stanfield KM, Trajkovic D and Knapp DW: Expression of cyclooxygenase-2 in canine renal cell carcinoma. Vet Pathol 38: 116-119, 2001.
16. Chen Q, Shinohara N, Abe T, Watanabe T, Nonomura K and Koyanagi T: Significance of COX-2 expression in human renal cell carcinoma cell lines. Int J Cancer 108: 825-832, 2004.
17. Xin X, Yang S, Kowalski J and Gerritsen ME: Peroxisome proliferator-activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 274: 9116-9121, 1999.
18. Rose DP and Connolly JM: Effects of fatty acids and inhibitors of eicosanoid synthesis on the growth of a human breast cancer cell line in culture. Cancer Res 50: 7139-7144, 1990.
19. Rose DP, Connolly JM, Rayburn J and Coleman M: Influence of diets containing eicosapentaenoic or docosahexaenoic acid on growth and metastasis of breast cancer cells in nude mice. J Natl Cancer Inst 87: 587-592, 1995.
20. Karmali RA, Reichel P, Cohen LA, Terano T, Hirai A, Tamura Y and Yoshida S: The effects of dietary omega-3 fatty acids on the du-145 transplantable human prostatic tumor. Anticancer Res 7: 1173-1179, 1987.
21. Prentice RL and Sheppard L: Dietary fat and cancer: consistency of the epidemiologic data, and disease prevention that may follow from a practical reduction in fat consumption. Cancer Causes Control 1: 81-109, 1990.
22. Stolzenberg-Solomon RZ, Pietinen P, Taylor PR, Virtamo J and Albanes D: Prospective study of diet and pancreatic cancer in male smokers. Am J Epidemiol 155: 783-792, 2002.
23. Takezaki T, Inoue M, Kataoka H, Ikeda S, Yoshida M, Ohashi Y, Tajima K and Tominaga S: Diet and lung cancer risk from a 14-year population-based prospective study in Japan: with special reference to fish consumption. Nutr Cancer 45: 160-167, 2003.
24. Savage DB: PPAR gamma as a metabolic regulator: insights from genomics and pharmacology. Expert Rev Mol Med 7: 1-16, 2005.
25. Knouff C and Auwerx J: Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev 25: 899-918, 2004.
26. Picard F and Auwerx J: PPAR(gamma) and glucose homeostasis. Annu Rev Nutr 22: 167-197, 2002.
27. Itoh T, Fairall L, Amin K, Inaba Y, Szanto A, Balint BL, Nagy L, Yamamoto K and Schwabe JW: Structural basis for the activation of PPARgamma by oxidized fatty acids. Nat Struct Mol Biol 15: 924-931, 2008.
28. Edwards IJ and O'Flaherty JT: Omega-3 fatty acids and PPARgamma in cancer. PPAR Res 2008: 358052, 2008.
29. Gani OA: Are fish oil omega-3 long-chain fatty acids and their derivatives peroxisome proliferator-activated receptor agonists? Cardiovasc Diabetol 7: 6, 2008.
30. Mansure JJ, Nassim R and Kassouf W: Peroxisome proliferator-activated receptor gamma in bladder cancer: a promising therapeutic target. Cancer Biol Ther 8: 6-15, 2009.
31. Roman J: Peroxisome proliferator-activated receptor gamma and lung cancer biology: implications for therapy. J Investig Med 56: 528-533, 2008.
32. Voutsadakis IA: Peroxisome proliferator-activated receptor gamma (PPARgamma) and colorectal carcinogenesis. J Cancer Res Clin Oncol 133: 917-928, 2007.
33. de Souza Pereira R: Selective cyclooxygenase-2 (COX-2) inhibitors used for preventing or regressing cancer. Recent Pat Anticancer Drug Discov 4: 157-163, 2009.
34. Harris RE: Cyclooxygenase-2 (cox-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung. Inflammopharmacology 17: 55-67, 2009.
35. Fujimura T, Ohta T, Oyama K, Miyashita T and Miwa K: Cyclooxygenase-2 (COX-2) in carcinogenesis and selective COX-2 inhibitors for chemoprevention in gastrointestinal cancers. J Gastrointest Cancer 38: 78-82, 2007.
36. Gilhooly EM and Rose DP: The association between a mutated ras gene and cyclooxygenase-2 expression in human breast cancer cell lines. Int J Oncol 15: 267-270, 1999.
37. Hussain T, Gupta S and Mukhtar H: Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 191: 125-135, 2003.
38. Lee KS, Lee HJ, Ahn KS, Kim SH, Nam D, Kim DK, Choi DY, Ahn KS, Lu J and Kim SH: Cyclooxygenase-2/prostaglandin e2 pathway mediates icariside II induced apoptosis in human PC-3 prostate cancer cells. Cancer Lett 280: 93-100, 2009.
39. Sun WH, Chen GS, Ou XL, Yang Y, Luo C, Zhang Y, Shao Y, Xu HC, Xiao B, Xue YP, Zhou SM, Zhao QS and Ding GX: Inhibition of COX-2 and activation of peroxisome proliferator-activated receptor gamma synergistically inhibits proliferation and induces apoptosis of human pancreatic carcinoma cells. Cancer Lett 275: 247-255, 2009.
40. Chen Q, Shinohara N, Abe T, Harabayashi T and Nonomura K: Impact of cyclooxygenase-2 gene expression on tumor invasiveness in a human renal cell carcinoma cell line. J Urol 172: 2153-2157, 2004.
41. Hemmerlein B, Galuschka L, Putzer N, Zischkau S and Heuser M: Comparative analysis of COX-2, vascular endothelial growth factor and microvessel density in human renal cell carcinomas. Histopathology 45: 603-611, 2004.
42. Bren-Mattison Y, Meyer AM, Van Putten V, Li H, Kuhn K, Stearman R, Weiser-Evans M, Winn RA, Heasley LE and Nemenoff RA: Antitumorigenic effects of peroxisome proliferator-activated receptor-gamma in non-small-cell lung cancer cells are mediated by suppression of cyclooxygenase-2 via inhibition of nuclear factor-kappaB. Mol Pharmacol 73: 709-717, 2008.
43. Chêne G, Dubourdeau M, Balard P, Escoubet-Lozach L, Orfila C, Berry A, Bernad J, Aries MF, Charveron M and Pipy B: n-3 and n-6 polyunsaturated fatty acids induce the expression of COX-2 via PPARgamma activation in human keratinocyte HaCaT cells. Biochim Biophys Acta 1771: 576-589, 2007.
44. Andrade LN, de Lima TM, Curi R, Castrucci AM: Toxicity of fatty acids on murine and human melanoma cell lines. Toxicol In Vitro 19: 553-560, 2005.
45. Azevedo-Martins AK, Monteiro AP, Lima CL, Lenzen S and Curi R: Fatty acid-induced toxicity and neutral lipid accumulation in insulin-producing RINm5F cells. Toxicol In Vitro 20: 1106-1113, 2006.
46. Otton R and Curi R: Toxicity of a mixture of fatty acids on human blood lymphocytes and leukaemia cell lines. Toxicol In Vitro 19: 749-755, 2005.